Quintrio
Home

Stock overview

Telix Pharmaceuticals Limited American Depositary Shares

TLX

Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.

Last trade $8.89
Day change -$0.03 (-0.34%)
Day range $8.84 – $9.07
Volume 173,392
Market cap $3.03B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for TLX.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TLX, quarterly periods
Line itemQ3 FY2010 Sep 30, 2010Q2 FY2010 Jun 30, 2010
Revenue$7.08M$6.27M
Cost of revenue$5.83M$5.11M
Gross profit$1.25M$1.16M
Selling, general and administrative$2.03M$2.35M
Research and development——
Total operating expenses$2.09M$3.39M
Operating income-$836K-$2.23M
Interest expense-$380K-$365K
Income before taxes-$1.22M-$2.59M
Income taxes$14K$14K
Net income-$1.23M-$2.61M
Net income attributable to common shareholders-$1.23M-$2.61M
EBITDA$540K-$1.18M
Basic earnings per share-$0.01-$0.03
Diluted earnings per share-$0.01-$0.03

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Telix Reports Third Quarter 2026 Financial Performance

Telix Pharmaceuticals reported Q3 2026 group revenue of US$245 million, up 19% year-over-year, driven by strong demand for PSMA imaging products Gozellix and Illuccix. The company received FDA approval for Pixclara for glioma imaging and announced a transformational merger with Isotope Technologies Munich (ITM) for US$1.65 billion upfront, creating a vertically integrated radiopharmaceutical company with expanded isotope production capabilities. Telix reaffirmed FY 2026 revenue guidance exceeding US$1 billion.

GlobeNewswire Inc.

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Telix Pharmaceuticals has partnered with Ekalia (a joint venture between IBA and Framatome) to establish dedicated U.S. production of astatine-211, a scarce alpha-emitting isotope for targeted alpha therapy. The collaboration will install IBA's alpha-beam cyclotron at Telix's RLS Radiopharmacies site near Philadelphia, securing long-term isotope access for Telix's pipeline including TLX102-Tx for glioblastoma, while also supporting third-party programs.

GlobeNewswire Inc.

Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix

Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate Astatine-211 production in the United States. The partnership will establish the first US production unit at RLS Trevose in Pennsylvania, with potential for further expansion. Telix will secure access to a portion of the production capacity to advance its alpha therapy pipeline.

GlobeNewswire Inc.

Ekalia franchit une étape importante dans le déploiement de l’astate-211 aux États-Unis grâce à un accord de collaboration avec Telix

Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate astatine-211 (At-211) production in the United States. The partnership will leverage Telix's radiopharmaceutical network (RLS Radiopharmacies) to establish the first US production facility in Trevose, Pennsylvania, addressing the current shortage of this promising alpha-emitting radioisotope for cancer therapies.

GlobeNewswire Inc.

Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive Growth

The global next generation antibody therapeutics market is projected to grow from USD 5.45 billion to USD 5.76 billion by 2035, with a modest 1% CAGR. Growth is driven by advances in biotechnology, targeted treatments, and expanding clinical pipelines for cancer, rare diseases, and cardiovascular conditions. Immunocytokines and combination therapies are expected to demonstrate the strongest growth potential, while North America is projected to maintain approximately 64% market share.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Apr 18, 2006$0.035May 2, 2006unknown
Jan 11, 2006$0.035Jan 31, 2006unknown
Oct 5, 2005$0.035Oct 28, 2005unknown
Jun 21, 2005$0.035Jul 15, 2005unknown
Apr 18, 2005$0.035Apr 29, 2005unknown

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.